Peripheral artery disease affects approximately 8.5 million adults in the United States, according to Centers for Disease Control estimates, yet the majority of cases go undiagnosed until the condition becomes symptomatic enough to disrupt daily life. The clinical case for earlier screening is strong: patients identified before the onset of critical limb ischemia have significantly better outcomes for both limb preservation and cardiovascular event reduction.
This article reviews what current evidence suggests about who should be screened for PAD, how screening is performed, and what happens after diagnosis.
Who Should Be Screened
Current guidelines from major cardiovascular societies converge on a set of high-risk populations that benefit from targeted screening. These include adults aged 65 and older, adults aged 50 to 64 with at least one risk factor for atherosclerosis, and adults under 50 with diabetes and one additional risk factor. Risk factors include current or prior smoking, diabetes mellitus, hypertension, dyslipidemia, and a family history of premature cardiovascular disease.
Patients who present with exertional leg pain, non-healing lower extremity wounds, or symptoms suggestive of critical limb ischemia warrant evaluation regardless of age or risk profile. In these cases, PAD is not merely a possibility but a working diagnosis until ruled out.
The Ankle-Brachial Index
The primary screening test for PAD is the ankle-brachial index, a ratio comparing systolic blood pressure at the ankle to systolic blood pressure at the brachial artery. A resting ABI at or below 0.90 is considered diagnostic for PAD. Values between 0.91 and 0.99 are borderline and may prompt exercise ABI testing, while values above 1.40 suggest arterial calcification and typically warrant alternative assessments such as toe-brachial index.
The test itself takes approximately 15 minutes and requires only a blood pressure cuff and a handheld Doppler probe. It is non-invasive, radiation-free, and widely available in cardiology and vascular medicine offices.
Confirmatory Imaging
When ABI results are abnormal or when the clinical picture warrants further characterization, follow-up imaging clarifies the location and severity of arterial narrowing. Duplex ultrasound is the most common next step and can map arterial flow through the lower extremities without contrast or radiation. CT angiography and magnetic resonance angiography offer higher anatomical detail and are typically used when interventional planning is under consideration.
What Treatment Looks Like
Management of PAD is layered and typically begins with aggressive cardiovascular risk factor modification. Smoking cessation is the single highest-impact intervention. Structured supervised exercise therapy, particularly walking programs, has been shown in multiple randomized trials to increase pain-free walking distance and maximal walking distance in patients with claudication.
Pharmacologic therapy addresses both symptom management and long-term risk. Statin therapy is standard for patients with PAD regardless of baseline lipid levels, given the elevated cardiovascular risk associated with the diagnosis. Antiplatelet therapy, typically aspirin or clopidogrel, is recommended for most symptomatic patients. Cilostazol may be considered specifically for patients with claudication who do not have heart failure.
For patients with lifestyle-limiting claudication despite conservative therapy, or for those presenting with critical limb ischemia, revascularization becomes appropriate. Endovascular approaches including balloon angioplasty, stent placement, and atherectomy have expanded significantly and now handle the majority of interventions. Surgical bypass remains a durable option for complex anatomy or long segment disease.
The Texas Context
In Texas, the combination of an aging population, high diabetes prevalence, and geographic dispersion has driven several community cardiology practices to expand peripheral vascular services. Groups offering PAD diagnosis and treatment Texas patients can access locally have become an important part of the care landscape, particularly in areas outside major metropolitan centers where specialty referrals historically involved significant travel.
Same-day non-invasive screening, on-site imaging, and outpatient catheterization capabilities under one roof reduce the friction that delays diagnosis. For patients in the Conroe, The Woodlands, and Huntsville corridor north of Houston, this integrated model has shortened the timeline from initial symptom presentation to treatment plan.
Prognosis and Follow-Up
Patients diagnosed with PAD warrant lifelong follow-up given the elevated risk of cardiovascular events. Serial ABI measurement, ongoing risk factor optimization, and regular clinical assessment of walking capacity and wound status form the backbone of continuing care.
The clinical message is straightforward: PAD is common, under-diagnosed, and treatable. Non-invasive screening is inexpensive, quick, and widely available. Adults in the high-risk groups described above should have an ABI at least once, and any adult with symptoms suggestive of arterial insufficiency should undergo evaluation without delay.
